Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (59)

I-05Ahmad Abuhelwa

Population pharmacokinetic and pharmacodynamic modelling of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression

Wednesday 09:50-11:15

I-12Joachim Almquist

Estimation of equipotent doses of the oral selective glucocorticoid receptor modulator (oSGRM) AZD9567 and prednisolone based on ex vivo TNFa inhibition after LPS stimulation

Wednesday 09:50-11:15

I-13Jokha AL-Qassabi

Predicting the Fraction Unbound (fu) and Plasma Drug Clearance Based on Known Changes in Albumin and Alpha1-Acid Glycoprotein Levels at Varying Degrees of Renal Impairment

Wednesday 09:50-11:15

I-16Million Arefayene

Population Pharmacokinetics (PK) and pharmacodynamics (PD) Modeling of anti-avß6 integrin Antibody (BG00011)

Wednesday 09:50-11:15

I-21Ioanna Athanasiadou

Hyperhydration effect on pharmacokinetic parameters of recombinant human erythropoietin in urine and serum doping control analysis

Wednesday 09:50-11:15

I-29Violeta Balbas-Martinez

Quantitative Systems Pharmacology model for the key Interleukins involved in Crohn’s Disease

Wednesday 09:50-11:15

I-35Francesco Bellanti

Application of Model-Based Meta-Analysis to evaluate the relationship between early biomarker to late stage clinical endpoints for the development of anti-asthmatic drugs

Wednesday 09:50-11:15

I-36Amina Bensalem

Nonlinear pharmacokinetics and concentration-effect relationship of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis

Wednesday 09:50-11:15

I-39Martin Bergstrand

Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling

Wednesday 09:50-11:15

I-40Jan Berkhout

Application of population PK/PD modeling and simulation to inform the design of a dose-finding study in patients with schizophrenia

Wednesday 09:50-11:15

I-57Antonio Cabal

Using multiscale mechanism based mathematical modeling to address many of the challenges associated with the estimation of local lung concentration after inhaled drug delivery

Wednesday 09:50-11:15

I-59Elisa Calvier

Alirocumab population pharmacokinetics in Chinese patients using priors

Wednesday 09:50-11:15

I-83Eva Maria del Amo Paez

Pharmacokinetics after intravitreal injection of a new anti-angiogenic therapeutic compound in rabbit eyes

Wednesday 09:50-11:15

I-84Francesca Del Bene

Intratympanic drug administration: a challenge for PK modelling

Wednesday 09:50-11:15

II-01Åsa Kragh

Population pharmacokinetic analysis of PT010, an inhaled triple fixed-dose combination product, in patients with chronic obstructive pulmonary disease

Wednesday 15:10-16:40

II-09Jacob Leander

Development of a population pharmacokinetic model of verinurad used for simulations of various dosing scenarios in different populations

Wednesday 15:10-16:40

II-11Woo Yul Lee

Population pharmacokinetics of recombinant coagulation factor VIII in Korean hemophila A patients

Wednesday 15:10-16:40

II-12Soyoung Lee

Population Pharmacokinetic Analysis for Novel Acid Pump Antagonist DWP14012

Wednesday 15:10-16:40

II-19Patrick Lilienthal

Mathematical modeling of RBC count dynamics after blood loss

Wednesday 15:10-16:40

II-23Rasmus Jansson Löfmark

Translational pharmacokinetic-pharmacodynamic modelling predicts human exposure target engagement

Wednesday 15:10-16:40

II-25Dominik Lott

Prediction of exposure and effect on total lymphocyte count following long-term treatment of healthy subjects and lupus patients with the selective S1P1 receptor modulator cenerimod

Wednesday 15:10-16:40

II-26Qiang Lu

Population Pharmacokinetic Meta-Analysis of Dupilumab in Adult Atopic Dermatitis Patients, Asthma Patients, and Healthy Subjects

Wednesday 15:10-16:40

II-35Mats Magnusson

Population PK and PASI exposure-response modelling for Certolizumab pegol in patients with chronic plaque psoriasis

Wednesday 15:10-16:40

II-43Christophe Meille

Combining BLRM and safety PKPD models to improve decision making in a phase I dose escalation study: case study of PCA062, an antibody drug conjugate targeting P-Cadherin

Wednesday 15:10-16:40

II-49Iris Minichmayr

Impact of genetic variants of UGT1A1 on myelosuppression during irinotecan therapy

Wednesday 15:10-16:40

II-52Camille Riff

Population Pharmacokinetics of Rituximab in patients with Chronic Lymphocytic Leukemia

Wednesday 15:10-16:40

II-56Ricardo Nalda-Molina

Evaluation of the predictive performance and the model adequacy of four population pharmacokinetic models of adalimumab in patients with inflammatory bowel disease.

Wednesday 15:10-16:40

II-57Srividya Neelakantan

Population Pharmacokinetic/Pharmacodynamic Modeling of PF-06480605, an Anti-TL1A Antibody, in Healthy Subjects and Ulcerative Colitis Patients

Wednesday 15:10-16:40

II-63Boram Ohk

Population pharmacokinetic analysis of tacrolimus: The role of integrative pharmacogenetics and pharmacometabolomics

Wednesday 15:10-16:40

II-65Sean Oosterholt

Model-based optimisation of N-acetylcysteine for the treatment of paracetamol overdose

Wednesday 15:10-16:40

II-69Robert Palmér

A novel joint modelling approach to estimating treatment effects on COPD exacerbations in the presence of differential discontinuations

Wednesday 15:10-16:40

II-77Philippe Pierrillas

PK-PD modelling of C4 concentrations after administration of a FXR agonist in healthy volunteers and Hepatitis B patients

Wednesday 15:10-16:40

II-79Vikram Prabhakar

QSP Model of Rheumatoid Arthritis, capturing range of clinical responses to Methotrexate and anti-TNF-a therapies

Wednesday 15:10-16:40

II-86Michael Reed

Evaluation of competitive differentiation of novel therapies and the impact of patient variability on efficacy in a psoriasis QSP platform

Wednesday 15:10-16:40

II-88Isabel Reinecke

Levonorgestrel-Containing Contraceptives: Comparison of Daily Doses and Exposure for Various Routes of Administration by an Integrated Population Pharmacokinetic Analysis

Wednesday 15:10-16:40

II-89Dinko Rekic

Higher Febuxostat Exposure observed in Japanese Compared to Caucasian Subjects Independent of Bodyweight

Wednesday 15:10-16:40

III-08Ryosuke Shimizu

Quantitative systems pharmacology modeling of thrombopoiesis and platelet life-cycle, and application for thrombocytopenia

Thursday 09:55-11:20

III-28Felix Stader

Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving age-related changes in drug exposure in the elderly

Thursday 09:55-11:20

III-32Sabine Stuebler

Systems biology model of the mucosal immune system

Thursday 09:55-11:20

III-41Mita Thapar

Population pharmacokinetic analysis of MSB11022 following administration in healthy subjects and rheumatoid arthritis patients.

Thursday 09:55-11:20

III-50David Uster

Predictive performance of population pharmacokinetic models for Bayesian forecasting of coagulation factor VIII in hemophilia A

Thursday 09:55-11:20

III-60Diego Vera-Yunca

Pharmacokinetic-Pharmacodynamic model for Acute Intermittent Porphyria in porphyric mice treated with a new recombinant PBGD protein

Thursday 09:55-11:20

III-64Ulrika Wählby Hamrén

Longitudinal FEV1 and exacerbation risk in COPD: Quantifying the association using joint modelling

Thursday 09:55-11:20

III-68Linda Wanika

Investigating the relationship between Lactate Dehydrogenase and the occurrence of Chronic Lower Respiratory Diseases

Thursday 09:55-11:20

III-90Tom Zwart

Population pharmacokinetics and limited sampling of iohexol as a renal function marker

Thursday 09:55-11:20

IV-05Vincent Duval

A continuous-time Markov model (CTMM) for investigator’s global assessment (IGA) score in moderate-to-severe atopic dermatitis treated with subcutaneous nemolizumab.

Thursday 15:25-16:50

IV-13Anam Fayyaz

Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes

Thursday 15:25-16:50

IV-14Anam Fayyaz

Development and Performance Verification of a semi-PBPK Model for Topical Ocular Delivery of Pilocarpine and Timolol to Rabbit Eyes

Thursday 15:25-16:50

IV-19Yu Fu

Hemodynamic systems model to characterize cardiovascular drug effects

Thursday 15:25-16:50

IV-22Masato Fukae

Population pharmacokinetic modeling of esaxerenone: a novel nonsteroidal mineralocorticoid receptor blocker

Thursday 15:25-16:50

IV-28Eva Germovsek

A time-to-event model relating integrated craving to risk of smoking relapse across different nicotine replacement therapy formulations

Thursday 15:25-16:50

IV-32Ignacio Gonzalez-Garcia

Pharmacokinetic/Pharmacodynamic Modelling of in vivo IL-13 Modulation by a monoclonal antibody (MEDI7836)

Thursday 15:25-16:50

IV-40

Population pharmacokinetics of cannabidiol in healthy subjects

Thursday 15:25-16:50

IV-53Chih-hsuan Hsin

Impact of intestinal and renal membrane transporter ABCB1 gene polymorphisms on the pharmacokinetics of digoxin in healthy Caucasian subjects

Thursday 15:25-16:50

IV-56Eman Ibrahim

Obesity and NAFLD activity score increase rate of fibrosis progression in a continuous-time Markov modelling of fibrosis progression in a long-term follow-up biopsy NAFLD cohort.

Thursday 15:25-16:50

IV-62Petra Jauslin

Modeling bounded scales for evaluation of treatment response to subcutaneous nemolizumab in moderate to severe atopic dermatitis

Thursday 15:25-16:50

IV-70Wannee kantasiripitak

A population pharmacokinetic and exposure-response model of golimumab for targeting endoscopic remission in patients with ulcerative colitis

Thursday 15:25-16:50

IV-80Zackary Kenz

Inflammation and Fibrosis in Nonalcoloholic Steatohepatitis (NASH) Characterized by a Mathematical Model

Thursday 15:25-16:50

IV-82NaYoung Kim

Development of predictive model for acute kidney injury after minimally invasive partial nephrectomy

Thursday 15:25-16:50